AbbVie 3rd-qtr financials beat expectations

30 October 2024

Shares of US pharma major AbbVie (NYSE: ABBV) edged up 2% to $193.12 today, after it announced financial results for the third quarter ended September 30, 2024.

Net revenue during the quarter rose by 3.8% on a reported basis versus the year-ago period to $14.46 billion, above estimates of $14.3 billion. Adjusted per-share income came in at $3.00 compared to Wall Street projections of $2.91.

Third-quarter diluted earnings per share (EPS) of $0.88 on a generally accepted accounting practices (GAAP) basis represent a decrease of 12.0%, adjusted Diluted EPS of $3.00, an increase of 1.7%. These results include an unfavorable impact of $0.04 per share related to acquired IPR&D and milestones expense. This was 3% above both consensus $2.92 and the high end of the guidance range of $2.88-$2.92.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical